ClinConnect ClinConnect Logo
Search / Trial NCT04830033

ENO Breathe vs Usual Care in COVID-19 Recovery

Launched by IMPERIAL COLLEGE LONDON · Mar 31, 2021

Trial Information

Current as of July 21, 2025

Completed

Keywords

ClinConnect Summary

BACKGROUND:

ENO Breathe is a breathing and wellbeing programme developed specifically for people recovering from COVID-19, who are still suffering from breathlessness and associated anxiety. Delivered by ENO in collaboration with Imperial College Healthcare teams entirely online, the programme focuses on breathing re-training through singing. Initial evaluation of the project suggested health improvements related to participation, however, a properly conducted efficacy study is needed.

DESIGN: An assessor blind, parallel group, randomised controlled trial, to assess the effects of ENO Bre...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults recovering from COVID-19 with ongoing breathlessness and/or anxiety.
  • Referred from a specialist COVID-19 clinics aligned with the project, after appropriate clinical evaluation and investigation
  • Internet access with appropriate device (e.g. computer or tablet)
  • Exclusion Criteria:
  • - Unable to participate due to comorbidity (e.g. life limiting illness, cognitive impairment)

About Imperial College London

Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.

Locations

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Nicholas S Hopkinson

Principal Investigator

Imperial College London

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials